Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8857152 | 0.87 | GRM2 (0.57) | GRM2CA2 | |
| SCHEMBL8857336 | 0.81 | GRM2 (0.60) | GRM2CA2 | |
| SCHEMBL27396525 | 0.81 | ENPP2 (0.40) | GRM2ENPP2 | |
| SCHEMBL8857660 | 0.81 | GRM2 (0.55) | GRM2CA2 | |
| SCHEMBL8975224 | 0.79 | GRM2 (0.45) | GRM2 | |
| SCHEMBL8975395 | 0.77 | GRM2 (0.44) | GRM2CA2 | |
| SCHEMBL8975195 | 0.76 | GRM2 (0.43) | GRM2CA2 | |
| SCHEMBL9235816 | 0.73 | GRM2 (0.55) | GRM2CA2 | |
| SCHEMBL8974665 | 0.72 | GRM2 (0.54) | GRM2CA2 | |
| SCHEMBL8975222 | 0.72 | GRM2 (0.54) | GRM2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |